Activation of AKT kinases in cancer: implications for therapeutic targeting.

By A. Bellacosa, C. Kumar, A. D. Cristofano, J. Testa. Advances in Cancer Research, 2005

830 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Epithelial–mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways (2005, background): “In fact, agents targeting these molecules are already available either as proof-ofprinciple agents (e.g. LY294002) or as formulations already in the clinic (IRESSA, Herceptin, farnesyltransferase inhibitors) (Bellacosa et al., 2005).”
Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial–mesenchymal transition (2005, background): “Deregulated, or enhanced, Akt signaling has also been implicated in a variety of human cancers, and may promote tumorigenesis (for review see Bellacosa et al., 2005).”
Perturbations of the AKT signaling pathway in human cancer (2005, background): “Collectively, these experimental findings suggest that blocking AKT signaling may not induce severe toxicity in normal tissues (reviewed in Bellacosa et al., 2005), although preclinical findings may not necessarily be predictive of clinical utility.”